A PROSPECTIVE INVESTIGATION OF THE IMPACT OF AGTR1 A1166C ON THE NEUROHORMONAL AND HEMODYNAMIC EFFECTS OF CANDESARTAN IN HEART FAILURE PATIENTS
Simon de Denus(Montreal Heart Institute), M. White, Michel Langlois, Melanie Phillips, Marie‐Claude Guertin, Anique Ducharme(Montreal Heart Institute), Marie‐Pierre Dubé(Montreal Heart Institute), Sylvie Provost(Montreal Heart Institute), Eileen O’Meara(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Jean‐Claude Lavoie(Centre Hospitalier Universitaire Sainte-Justine), Ian Mongrain(Montreal Heart Institute), Nadia Giannetti(Inserm), A. Mansour(Montreal Heart Institute), Jacques Turgeon(Unknown), Valérie Normand(Montreal Heart Institute), Thao Huynh(AstraZeneca (United Kingdom)), J.‐C. Tardif, Jean L. Rouleau(Montreal Heart Institute), M Leblanc, René Fouodjio(Montreal Heart Institute), R. C. Sheppard(Northside Hospital), Serge Lepage
Cited by 0
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart Failure
|New England Journal of Medicine|2010|1.8k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k